Clinical Trial Update: Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

View source ↗

Summary

Durvalumab (Imfinzi) is studied in a Japan post-marketing surveillance PMS for biliary tract cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Biliary Tract Cancer | Status: COMPLETED